Bellevue Group AG Buys 100,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Bellevue Group AG lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,071,615 shares of the biopharmaceutical company's stock after acquiring an additional 100,000 shares during the period. Celldex Therapeutics makes up approximately 1.7% of Bellevue Group AG's portfolio, making the stock its 16th biggest position. Bellevue Group AG owned approximately 4.63% of Celldex Therapeutics worth $104,404,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CLDX. Vanguard Group Inc. grew its stake in Celldex Therapeutics by 19.8% in the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company's stock valued at $153,215,000 after acquiring an additional 604,251 shares during the period. Point72 Asset Management L.P. grew its position in Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company's stock valued at $71,725,000 after purchasing an additional 654,194 shares during the period. Marshall Wace LLP grew its position in Celldex Therapeutics by 53.3% in the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company's stock valued at $50,995,000 after purchasing an additional 479,068 shares during the period. Jennison Associates LLC raised its holdings in Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock worth $45,017,000 after buying an additional 321,325 shares during the last quarter. Finally, Novo Holdings A S raised its holdings in Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company's stock worth $32,755,000 after buying an additional 113,663 shares during the last quarter.

Celldex Therapeutics Trading Down 1.6 %

Shares of CLDX traded down $0.45 on Friday, reaching $27.44. 340,442 shares of the company's stock traded hands, compared to its average volume of 1,104,933. The stock's 50 day simple moving average is $28.81 and its two-hundred day simple moving average is $34.39. The stock has a market cap of $1.82 billion, a PE ratio of -10.68 and a beta of 1.60. Celldex Therapeutics, Inc. has a 52-week low of $22.93 and a 52-week high of $53.18.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CLDX. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They set a "neutral" rating and a $45.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, November 20th. Wolfe Research downgraded Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. Wells Fargo & Company raised Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 26th. Finally, Citigroup initiated coverage on Celldex Therapeutics in a report on Monday, October 7th. They set a "buy" rating and a $70.00 price target for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $62.25.

Insider Buying and Selling at Celldex Therapeutics

In related news, CEO Anthony S. Marucci bought 11,500 shares of the company's stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the purchase, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 3.80% of the company's stock.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.